NRx is developing treatments for central nervous system disorders including suicidal depression, chronic pain, and PTSD. Its lead candidates include NRX-100, an intravenous ketamine formulation that ...

Revenue: Approximately $240,000 for the third quarter, reflecting 22 days of operations from a single clinic group. Loss from Operations: $4 million for Q3 2025, compared to $3 million in Q3 2024.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NRX Pharmaceuticals ( (NRXP)) has issued ...

Sean is a JDM and off-road enthusiast of many years, and an automotive photographer. He holds a B.A. in Literature and Writing Studies, an A.A. in Communications, and an A.A. in English. He is ...

The SR-71 may be a retired Cold War-era enterprise, but the infamous aircraft retains several world records, beating out even the more advanced fifth-generation jets in service today. Back in the ...

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) shares are moving higher on Tuesday after it oversaw an investment of $27 million in its subsidiary HOPE Therapeutics. The Details: The purpose of the ...

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), announced Thursday its plans to acquire Kadima Neuropsychiatry Institute, a La Jolla, CA-based interventional psychiatric clinic, ...

NRX Pharmaceuticals (NASDAQ:NRXP) shares are trading higher on Thursday after the company’s Hope Therapeutics subsidiary announced the planed acquisition of Kadima Neuropsychiatry Institute. The ...

SR Suntour has released new versions of its Durolux38-Evo and Auron36-Evo forks for 2025, featuring a fresh RC+ PCS damper that's said to be the brand's most responsive yet. The new damper uses an ...

Net Operating Loss Reduction: 74% reduction in net operating losses compared to Q3 2023. Net Loss: Reduced to $1.6 million in Q3 2024 from $6.1 million in Q3 2023. Research and Development Expenses: ...